Nipruss (Sodium Nitroprusside Dihydrate)

Sodium Nitroprusside Dihydrate, the active ingredient in Nipruss, is a nitrovasodilator presented as an injectable solution for intravenous use. It produces rapid, controlled reduction of blood pressure in hypertensive emergencies, supports hemodynamic management in acute heart failure, and enables precise hypotension during surgical procedures.

GNH USA supplies Nipruss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for critical care settings and ensuring product integrity throughout the supply chain.

Nipruss is a nitrovasodilator used in critical cardiovascular situations where rapid blood‑pressure control is required.

- Hypertensive emergencies: provides immediate, titratable reduction of severe arterial pressure. - Acute heart failure: improves cardiac output by decreasing afterload and preload. - Controlled hypotension during surgery: allows precise lowering of blood pressure to reduce bleeding and improve surgical field visibility.

Nipruss may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often related to rapid blood‑pressure changes. - Nausea: occasional gastrointestinal discomfort. - Flushing: transient redness of the skin. - Hypotension: excessive drop in blood pressure if dosing is not carefully titrated. - Methemoglobinemia: elevation of methemoglobin levels, usually dose‑related. - Cyanide toxicity: accumulation of cyanide metabolites with prolonged high‑dose infusions.

Serious or Rare Side Effects: - Cardiac arrhythmias: potentially life‑threatening rhythm disturbances. - Severe hypotension: may lead to organ hypoperfusion. - Anaphylactoid reactions: rare hypersensitivity responses. - Renal impairment: worsening kidney function in susceptible patients. - Pulmonary edema: fluid accumulation in the lungs. - Acute liver injury: rare hepatic dysfunction.

Before initiating therapy with Nipruss, clinicians should consider several safety measures.

- Blood pressure monitoring: continuous arterial pressure measurement is essential for dose titration. - Cardiac function assessment: evaluate for pre‑existing heart block or severe left‑ventricular dysfunction. - Methemoglobin levels: monitor especially in patients with G6PD deficiency or prolonged infusion. - Cyanide exposure: limit infusion duration and consider sodium thiosulfate in high‑risk cases. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus (Category C). - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Nipruss can interact with several agents that affect vascular tone or cyanide metabolism.

Major Interactions (Avoid): - Other vasodilators (e.g., nitroglycerin, hydralazine): may cause profound hypotension. - Sodium thiosulfate high doses: can alter cyanide detoxification pathways. - MAO inhibitors: increase risk of hypertensive crisis when combined with certain catecholamines.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance the hypotensive effect. - Beta‑blockers: may mask tachycardia response to hypotension. - ACE inhibitors/ARBs: additive blood‑pressure lowering effect. - Calcium channel blockers: potential for excessive vasodilation. - Anticoagulants: monitor for bleeding if hypotension leads to tissue hypoperfusion.